BA
HZNP

Bivin & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bivin & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 443
2021
Q4 		$1K Buy
+10
New +$1.09K ﹤0.01% 392

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bivin & Associates's HZNP Position: Q1 2022 in Review

Bivin & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Bivin & Associates first reported a position in HZNP in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • Bivin & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Bivin & Associates sold 10 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $1K.
  • Bivin & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 1 quarter.
  • Bivin & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q4 2021.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.